We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. The pharma industry witnessed solid growth amid the pandemic. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. Trading CFDs is high risk and is not suitable for everyone. Forecast . The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. Real-time analyst ratings, insider transactions, earnings data, and more. Abbvie Stock Forecast | Is Abbvie a Good Stock to Buy? - Capital Compare Top Brokerages Here. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . The company didn't offer a . RHHBY vs. ABBV: Which Stock Is the Better Value Option? The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Having so much debt in a prevailing inflationary environment is also unattractive. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Here's Exactly How AbbVie Stock Can Beat the Market In 2023 It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. See what's happening in the market right now with MarketBeat's real-time news feed. I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. The total revenue in 2021 was $56.20 billion with a 31% operating margin. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. It now expects full-year profit in the range of $13.92-$14.12 a share. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Slide from JPM Conference 2022 presentation. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Abbvie Stock Forecast: up to 179.050 USD! - Walletinvestor.com You should consider whether you understand how CFDs work and can afford the risks. Neurology also looks strong although aesthetics, eye care and oncology have something to prove. Move your mouse over a quarter or year to see how estimates have changed over time. AbbVie Inc. (ABBV) Stock Forecast & Price Targets - Stock Analysis Let's begin our analysis with the immunology division. I wrote this article myself, and it expresses my own opinions. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. . AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. I write about Biotech, Pharma and Healthcare stocks and share investment tips. 67.71% of the stock of AbbVie is held by institutions. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. The company provided earnings per share (EPS) guidance of $10.70- for the period. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. And it couldnt be more wrong! Morningstar: 2019 Morningstar, Inc. All Rights Reserved. In-depth profiles and analysis for 20,000 public companies. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. This suggests a possible upside of 3.8% from the stock's current price. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. GSK Stock Forecast 2023 - 2025 - 2030 | StockForecast.com Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. AbbVie has been increasing its dividend for 51 years. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. Finally, AbbVie was able to raise its financial . Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. I wrote this article myself, and it expresses my own opinions. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Should I buy or sell AbbVie stock right now? This suggests a possible upside of 3.2% from the stock's current price. Factset: FactSet Research Systems Inc.2019. American Consumer News, LLC dba MarketBeat 2010-2023. This could present more profit potential for drugmakers as well as investors. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. CNN Sans & 2016 Cable News Network. Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. All Rights Reserved. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. Sign in to your free account to enjoy all that MarketBeat has to offer. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. Payout ratios above 75% are not desirable because they may not be sustainable. on the strength of its future rather than present portfolio. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. Multidrug Resistant Bacteria Treatment Market - MarketWatch For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance AbbVie Inc. (ABBV) Stock Forecast & Price Prediction For 2023 2024 2025 Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Always do your own research on a stocks price performance and predictions before making an investment. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. . One share of ABBV stock can currently be purchased for approximately $156.06. The eye-disease markets are very large - Regeneron's Eylea is a >$7bn per annum selling drug and AMD markets are >$20bn in size. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. AbbVie projected sales - immunology (my forecasts and assumptions). The difference between trading assets and CFDs. A Warner Bros. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. This means that . We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. I have no business relationship with any company whose stock is mentioned in this article. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. Is this happening to you frequently? Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. (my tables). I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. AbbVie (ABBV) Stock Forecast & Price Target - TipRanks For the next eight years, the forecast is for Free Cash Flow to grow by . The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. The surge in revenues can primarily be attributed to its Allergan. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Over the years, AbbView Inc. has made numerous acquisitions. With a 5-year investment, the revenue is expected to be around +88.28%. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. Their ABBV share price forecasts range from $140.00 to $200.00. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. Read our dividend analysis for ABBV. View which stocks are hot on social media with MarketBeat's trending stocks report. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Better Buy: AbbVie vs. Johnson & Johnson | The Motley Fool I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more.